Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sacubitril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME known ✓ | P08473 | 12/20 | 0.63 |
| ▸ | ACE | P12821 | 4/20 | 0.63 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sacubitril SCHEMBL28471087 | 1.00 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239967 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239966 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239956 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL29554043 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL21239957 | 0.98 | MME (0.63) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059569 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL18059568 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL1908525 | 0.90 | MME (0.77) | MMEACEMMEL1 | |
| Sacubitril SCHEMBL8214132 | 0.90 | MME (0.77) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112666294-B | Method for separating and determining Shakubatu calcium salt and impurities thereof | 重庆三圣实业股份有限公司 | 2022-08-16 | — | — | CN | claimed |
| US-12508246-B2 | Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025051215-A1 | ARNI COMPOUND CALCIUM-SODIUM COMPLEX AS WELL AS CRYSTAL FORMS THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| WO-2024063537-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL VALSARTAN CALCIUM SALT | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2024-03-28 | — | — | WO | disclosed |
| US-11786498-B2 | Sacubitril calcium salts | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | disclosed |
| US-11629120-B2 | Trisodium sacubitril valsartan and process for its preparation | BIOCON LIMITED (IN) | 2023-04-18 | — | — | US | disclosed |
| CN-115677521-A | Preparation method of high-purity Shakuba kojie calcium | 迪嘉药业集团股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677521-A | Preparation method of high-purity Shakuba kojie calcium | 迪嘉药业集团股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220395491-A1 | USES OF COMPLEX OF ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR IN TREATING HEART FAILURE | SHENZHEN SALUBRIS PHARMACEUTICALS CO. LTD. (CN) | 2022-12-15 | — | — | US | disclosed |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2022-08-30 | — | — | US | disclosed |
| CN-112666294-B | Method for separating and determining Shakubatu calcium salt and impurities thereof | 重庆三圣实业股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-112666294-B | Method for separating and determining Shakubatu calcium salt and impurities thereof | 重庆三圣实业股份有限公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-4032532-A1 | USES OF COMPLEX OF ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR IN TREATING HEART FAILURE | Shenzhen Salubris Pharmaceuticals Co. Ltd (CN) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022139495-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL VALSARTAN HYBRID COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | 주식회사 보령 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022111493-A1 | PHARMACEUTICAL USE OF COMPLEX OF ARB METABOLITE AND NEP INHIBITOR IN PREVENTION AND/OR TREATMENT OF NEPHROPATHY | 深圳信立泰药业股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-11318116-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | LAURUS LABS LIMITED (IN) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318116-B2 | Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof | AGT, ACE, REN | MME 26/4885ACE 2/4885MMEL1 2441/4885 |
| US-12508246-B2 | Uses of complex of angiotensin II receptor antagonist metabolite and NEP inhibitor in treating heart failure | AGTR2, AGTR1, MME | MME 3/4885ACE 6/4885MMEL1 575/4885 |
| US-11426375-B2 | Substituted bisphenyl butanoic ester derivatives as NEP inhibitors | MME, REN, ECE1 | MME 1/4885ACE 4/4885MMEL1 606/4885 |
| US-11629120-B2 | Trisodium sacubitril valsartan and process for its preparation | AGT, ACE, REN | MME 7/4885ACE 2/4885MMEL1 276/4885 |
| US-20220395491-A1 | USES OF COMPLEX OF ANGIOTENSIN II RECEPTOR ANTAGONIST METABOLITE AND NEP INHIBITOR IN TREATING HEART FAILURE | MME, AGTR2, AGTR1 | MME 1/4885ACE 4/4885MMEL1 132/4885 |
| US-11786498-B2 | Sacubitril calcium salts | DNPEP, BPGM, CACNA1S | MME 8/4885ACE 31/4885MMEL1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.